Borradori, Luca, Simon, Dagmar, Cazzaniga, Simone, Sonntag, Anne‐Katharina, Piletta, Pierre, Huber, Caroline, Diepgen, Thomas L., Apfelbacher, Christian, Naldi, Luigi, Gräni, Nora, Ballmer‐Weber, Barbara K., Spring, Philippe, Bircher, Andreas, and Anliker, Mark
Subjects
*ECZEMA, *QUALITY of life, *CHRONIC diseases, *DISEASE progression, HEALTH of patients
Abstract
Background: Hand eczema (HE) is common and may follow a chronic disease course. So far, prospective studies investigating the risk factors for disease progression as a prerequisite for targeted prevention are scarce. Objective: To evaluate the overall association of HE‐associated factors with clinical and quality of life (QoL) improvement during a follow‐up of 2 years. Methods: Data of the prospective patient cohort (N = 199) followed by the Swiss chronic HE (CHE) registry on long‐term patient management (CARPE‐CH) were analysed by means of both classic regression and semantic map analyses. Results: Both severity of HE and QoL significantly improved over the period of 2 years (P < .001). However, 20% of patients had moderate to severe HE after 2 years of follow‐up. As factors associated with an unfavourable CHE clinical course and QoL, environmental exposures, male sex, occupational skin disease, job loss or change at baseline, allergic contact dermatitis, a chronic disease course, palmar localization and widespread eczema were identified. Conclusions: Analysis of prospective data from CARPE‐CH shows a complex pattern of associations among variables as shown by semantic map and classic statistical analyses. Factors related to occupational exposure had the highest impact on CHE. [ABSTRACT FROM AUTHOR]
Of 131 patch-test positive patients, 24 (18.3%) reacted to both preparations, 98 (74.8%) to FMI only, and 9 (6.9%) to OM and not to FMI, although OM is a constituent of FMI. Keywords: allergic contact dermatitis; delayed reactions; fragrance; fragrance mix I; late reactions; oak moss absolute; patch test; patch test active sensitization EN allergic contact dermatitis delayed reactions fragrance fragrance mix I late reactions oak moss absolute patch test patch test active sensitization 54 57 4 12/17/21 20220101 NES 220101 Patch test reactions that become positive de novo at around day 7 (D7) are called "late" patch test reactions,1 and are frequently seen after patch testing neomycin, for example.2 Reactions beyond D7 ("very late reactions") may indicate active sensitization.1,3 However, very late reactions (2 to 4 weeks after patch testing) without being linked to active sensitization have also been observed.4-6 We were interested in very late reactions (beyond D7) in patch testing fragrance mix I (FMI) and oak moss absolute (OM). Regarding all positive reactions, 11/136 (8.1%) of FMI-positive patients and 11/45 (24.4%) of OM-positive patients showed very late reactions (Table 1). 1 TABLEResults of reading fragrance mix I (FMI) and oak moss absolute (OM) in n = 1789 patients at different points of time HT
N patients
Positive D3(D4)
% D3(D4)
Late positive D4-D7
Very late positive. Allergic contact dermatitis, delayed reactions, fragrance, late reactions, oak moss absolute, patch test, patch test active sensitization, fragrance mix I. [Extracted from the article]
Background: Allergic contact dermatitis caused by shoes is common and new relevant allergens have been identified. Objectives: To investigate the pattern of type IV sensitization in patients with suspected allergic contact dermatitis of the feet related to shoes as a presumed culprit trigger. Methods: Retrospective analysis of data of the Information Network of Departments of Dermatology (IVDK), 2009‐2018. Results: Six hundred twenty‐five patients with presumed shoe dermatitis were identified in a cohort of 119 417 patients. Compared to patients with suspected contact sensitization from other allergen sources (n = 118 792), study group patients were more frequently sensitized to potassium dichromate (10.8% vs 3.5%), colophony (7.2% vs 3.7%), mercaptobenzothiazole (MBT; 4.0% vs 0.6%), mercapto mix (4.6% vs 0.6%), and p‐tert‐butylphenol formaldehyde resin (1.6% vs 0.5%). Sensitizations to urea formaldehyde resin, melamine formaldehyde resin, glutaraldehyde, tricresyl phosphate, and phenyl glycidylether were rare. Moreover, reactions to compounds in the leather or textile dyes test series were scarce. Conclusion: A distinct sensitization pattern was observed in patients with suspected allergy to shoe materials. Although substances with low sensitization rates should be removed from the leather and shoe patch test series, novel potential allergens should be added. [ABSTRACT FROM AUTHOR]
Remarkably, our results are comparable with those of clinical and real-life studies, although exclusively patients with severe AD were eligible to get dupilumab therapy. SP S5-S11,S14,S15 sp Already one month after initiating dupilumab therapy, 60% reported that AD did not or minimally affected their quality of life (Figure 1). Keywords: atopic dermatitis; dupilumab; epidermal barrier; interleukin-13; type 2 inflammation EN atopic dermatitis dupilumab epidermal barrier interleukin-13 type 2 inflammation 1268 1270 3 04/14/21 20210401 NES 210401 The pathogenesis of atopic dermatitis (AD), a common chronic inflammatory skin disease, is based on a genetic predisposition that determines both skin barrier function and type 2 immune reaction.1,2 SP ,S1-S4 sp Type 2 cytokines may further impair the epidermal barrier and trigger AD inflammation.1 Therapy with dupilumab that inhibits the action of interleukin (IL)-4 and IL-13 by blocking the shared receptor results in a rapid improvement of symptoms, clinical signs, and quality of life in AD patients.3 SP ,S5-S11 sp Transcriptome analyses of skin samples suggest that it affects mRNA expression of genes related to type 2 inflammation, T helper (Th)17/Th22 pathways, dendritic cells, epidermal barrier, and lipid metabolism.4,5 SP ,S12-S13 sp This study aimed at assessing the efficacy and safety of dupilumab therapy in patients with AD referred to a tertiary center and at investigating the effect of dupilumab on both inflammation and epidermal barrier by applying immunofluorescence techniques. [Extracted from the article]
The article presents a case study on 10 patients suffering from severe cutaneous drug eruptions. The patients have developed widespread eczema, as well as erythematous, maculopapular, erythema multiforme-like and blistering eruption after the initiation of antifungal therapy. The article also discusses the culprit drugs used by patients that have caused severe infections.
Focuses on a study which explained the existence and activation of CD8+ T cells in eczema lesions contributing to immunoglobulin E production and eosinophil survival and development, chronicity and exacerbation of atopic dermatitis (AD). Classification of AD as a skin disease; Role played by T cells in both AD and contact dermatitis; Way in which additional evidence for in vivo activation of CLA+ T cells appears.